Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 31 entries
Sorted by: Best Match Show Resources per page
Monitor: molecules and profiles.

Drug discovery today

Westwell AD, Langston S.
PMID: 11166258
Drug Discov Today. 2001 Jan 01;6(2):102-104. doi: 10.1016/s1359-6446(00)01641-x.

Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance...

Cite
Westwell AD, Langston S. Monitor: molecules and profiles. Drug Discov Today. 2001;6(2):102-104doi: 10.1016/s1359-6446(00)01641-x.
Westwell, A. D., & Langston, S. (2001). Monitor: molecules and profiles. Drug discovery today, 6(2), 102-104. https://doi.org/10.1016/s1359-6446(00)01641-x
Westwell, A D., and Langston, S. "Monitor: molecules and profiles." Drug discovery today vol. 6,2 (2001): 102-104. doi: https://doi.org/10.1016/s1359-6446(00)01641-x
Westwell AD, Langston S. Monitor: molecules and profiles. Drug Discov Today. 2001 Jan 01;6(2):102-104. doi: 10.1016/s1359-6446(00)01641-x. PMID: 11166258.
Copy Download .nbib Format: NLM
Novel antitumour molecules.

Drug discovery today

Westwell A.
PMID: 11344036
Drug Discov Today. 2001 May 01;6(9):489-491. doi: 10.1016/s1359-6446(01)01755-x.

No abstract available.

Cite
Westwell A. Novel antitumour molecules. Drug Discov Today. 2001;6(9):489-491doi: 10.1016/s1359-6446(01)01755-x.
Westwell, A. (2001). Novel antitumour molecules. Drug discovery today, 6(9), 489-491. https://doi.org/10.1016/s1359-6446(01)01755-x
Westwell, A. "Novel antitumour molecules." Drug discovery today vol. 6,9 (2001): 489-491. doi: https://doi.org/10.1016/s1359-6446(01)01755-x
Westwell A. Novel antitumour molecules. Drug Discov Today. 2001 May 01;6(9):489-491. doi: 10.1016/s1359-6446(01)01755-x. PMID: 11344036.
Copy Download .nbib Format: NLM
The Anti-mycobacterial Activity of a Diterpenoid-Like Molecule Operates Through Nitrogen and Amino Acid Starvation.

Frontiers in microbiology

Crusco A, Baptista R, Bhowmick S, Beckmann M, Mur LAJ, Westwell AD, Hoffmann KF.
PMID: 31293560
Front Microbiol. 2019 Jun 25;10:1444. doi: 10.3389/fmicb.2019.01444. eCollection 2019.

A library of 14 minimally cytotoxic diterpenoid-like compounds (CC

Cite
Crusco A, Baptista R, Bhowmick S, et al. The Anti-mycobacterial Activity of a Diterpenoid-Like Molecule Operates Through Nitrogen and Amino Acid Starvation. Front Microbiol. 2019;10:1444doi: 10.3389/fmicb.2019.01444.
Crusco, A., Baptista, R., Bhowmick, S., Beckmann, M., Mur, L. A. J., Westwell, A. D., & Hoffmann, K. F. (2019). The Anti-mycobacterial Activity of a Diterpenoid-Like Molecule Operates Through Nitrogen and Amino Acid Starvation. Frontiers in microbiology, 101444. https://doi.org/10.3389/fmicb.2019.01444
Crusco, Alessandra, et al. "The Anti-mycobacterial Activity of a Diterpenoid-Like Molecule Operates Through Nitrogen and Amino Acid Starvation." Frontiers in microbiology vol. 10 (2019): 1444. doi: https://doi.org/10.3389/fmicb.2019.01444
Crusco A, Baptista R, Bhowmick S, Beckmann M, Mur LAJ, Westwell AD, Hoffmann KF. The Anti-mycobacterial Activity of a Diterpenoid-Like Molecule Operates Through Nitrogen and Amino Acid Starvation. Front Microbiol. 2019 Jun 25;10:1444. doi: 10.3389/fmicb.2019.01444. eCollection 2019. PMID: 31293560; PMCID: PMC6603307.
Copy Download .nbib Format: NLM
Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers.

Immunology

Scurr MJ, Zelek WM, Lippiatt G, Somerville M, Burnell SEA, Capitani L, Davies K, Lawton H, Tozer T, Rees T, Roberts K, Evans M, Jackson A, Young C, Fairclough L, Tighe P, Wills M, Westwell AD, Morgan BP, Gallimore A, Godkin A.
PMID: 34775604
Immunology. 2022 Feb;165(2):250-259. doi: 10.1111/imm.13433. Epub 2021 Dec 06.

Accurate assessment of SARS-CoV-2 immunity is critical in evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS-CoV-2-specific T-cell responses are a critical feature that will likely form a key...

Cite
Scurr MJ, Zelek WM, Lippiatt G, et al. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. Immunology. 2021;165(2):250-259doi: 10.1111/imm.13433.
Scurr, M. J., Zelek, W. M., Lippiatt, G., Somerville, M., Burnell, S. E. A., Capitani, L., Davies, K., Lawton, H., Tozer, T., Rees, T., Roberts, K., Evans, M., Jackson, A., Young, C., Fairclough, L., Tighe, P., Wills, M., Westwell, A. D., Morgan, B. P., Gallimore, A., & Godkin, A. (2022). Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. Immunology, 165(2), 250-259. https://doi.org/10.1111/imm.13433
Scurr, Martin J, et al. "Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers." Immunology vol. 165,2 (2022): 250-259. doi: https://doi.org/10.1111/imm.13433
Scurr MJ, Zelek WM, Lippiatt G, Somerville M, Burnell SEA, Capitani L, Davies K, Lawton H, Tozer T, Rees T, Roberts K, Evans M, Jackson A, Young C, Fairclough L, Tighe P, Wills M, Westwell AD, Morgan BP, Gallimore A, Godkin A. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. Immunology. 2022 Feb;165(2):250-259. doi: 10.1111/imm.13433. Epub 2021 Dec 06. PMID: 34775604; PMCID: PMC8653009.
Copy Download .nbib Format: NLM
Novel antitumour molecules.

Drug discovery today

Westwell A.
PMID: 11173270
Drug Discov Today. 2001 Feb 01;6(4):215-216. doi: 10.1016/s1359-6446(00)01619-6.

Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance...

Cite
Westwell A. Novel antitumour molecules. Drug Discov Today. 2001;6(4):215-216doi: 10.1016/s1359-6446(00)01619-6.
Westwell, A. (2001). Novel antitumour molecules. Drug discovery today, 6(4), 215-216. https://doi.org/10.1016/s1359-6446(00)01619-6
Westwell, A. "Novel antitumour molecules." Drug discovery today vol. 6,4 (2001): 215-216. doi: https://doi.org/10.1016/s1359-6446(00)01619-6
Westwell A. Novel antitumour molecules. Drug Discov Today. 2001 Feb 01;6(4):215-216. doi: 10.1016/s1359-6446(00)01619-6. PMID: 11173270.
Copy Download .nbib Format: NLM
Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents.

MedChemComm

Bassetto M, Ferla S, Giancotti G, Pertusati F, Westwell AD, Brancale A, McGuigan C.
PMID: 30108852
Medchemcomm. 2017 May 26;8(7):1414-1420. doi: 10.1039/c7md00164a. eCollection 2017 Jul 01.

Prostate cancer is a major cause of male death worldwide and the identification of new efficient treatments is constantly needed. Different non-steroidal androgen receptor antagonists are approved also in the case of castration-resistant cancer forms. Using a rational approach...

Cite
Bassetto M, Ferla S, Giancotti G, et al. Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents. Medchemcomm. 2017;8(7):1414-1420doi: 10.1039/c7md00164a.
Bassetto, M., Ferla, S., Giancotti, G., Pertusati, F., Westwell, A. D., Brancale, A., & McGuigan, C. (2017). Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents. MedChemComm, 8(7), 1414-1420. https://doi.org/10.1039/c7md00164a
Bassetto, Marcella, et al. "Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents." MedChemComm vol. 8,7 (2017): 1414-1420. doi: https://doi.org/10.1039/c7md00164a
Bassetto M, Ferla S, Giancotti G, Pertusati F, Westwell AD, Brancale A, McGuigan C. Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents. Medchemcomm. 2017 May 26;8(7):1414-1420. doi: 10.1039/c7md00164a. eCollection 2017 Jul 01. PMID: 30108852; PMCID: PMC6072516.
Copy Download .nbib Format: NLM
Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757].

Nanomedicine : nanotechnology, biology, and medicine

Haynes B, Zhang Y, Liu F, Li J, Petit S, Kothayer H, Bao X, Westwell AD, Mao G, Shekhar MP.
PMID: 30726707
Nanomedicine. 2019 Jun;18:426. doi: 10.1016/j.nano.2019.01.005. Epub 2019 Feb 03.

No abstract available.

Cite
Haynes B, Zhang Y, Liu F, et al. Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757]. Nanomedicine. 2019;18:426doi: 10.1016/j.nano.2019.01.005.
Haynes, B., Zhang, Y., Liu, F., Li, J., Petit, S., Kothayer, H., Bao, X., Westwell, A. D., Mao, G., & Shekhar, M. P. (2019). Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757]. Nanomedicine : nanotechnology, biology, and medicine, 18426. https://doi.org/10.1016/j.nano.2019.01.005
Haynes, Brittany, et al. "Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757]." Nanomedicine : nanotechnology, biology, and medicine vol. 18 (2019): 426. doi: https://doi.org/10.1016/j.nano.2019.01.005
Haynes B, Zhang Y, Liu F, Li J, Petit S, Kothayer H, Bao X, Westwell AD, Mao G, Shekhar MP. Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757]. Nanomedicine. 2019 Jun;18:426. doi: 10.1016/j.nano.2019.01.005. Epub 2019 Feb 03. PMID: 30726707.
Copy Download .nbib Format: NLM
Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer.

Oncotarget

Kourti M, Westwell A, Jiang W, Cai J.
PMID: 30800223
Oncotarget. 2019 Feb 01;10(10):1132-1148. doi: 10.18632/oncotarget.26638. eCollection 2019 Feb 01.

Triple-negative breast cancer (TNBC) is defined by the lack of expression of the oestrogen and progesterone receptors and HER-2. Recently, carbon monoxide (CO) was found to behave as an important endogenous signalling molecule and to suppress VEGF receptor-2 (VEGFR-2)...

Cite
Kourti M, Westwell A, Jiang W, et al. Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer. Oncotarget. 2019;10(10):1132-1148doi: 10.18632/oncotarget.26638.
Kourti, M., Westwell, A., Jiang, W., & Cai, J. (2019). Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer. Oncotarget, 10(10), 1132-1148. https://doi.org/10.18632/oncotarget.26638
Kourti, Malamati, et al. "Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer." Oncotarget vol. 10,10 (2019): 1132-1148. doi: https://doi.org/10.18632/oncotarget.26638
Kourti M, Westwell A, Jiang W, Cai J. Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer. Oncotarget. 2019 Feb 01;10(10):1132-1148. doi: 10.18632/oncotarget.26638. eCollection 2019 Feb 01. PMID: 30800223; PMCID: PMC6383690.
Copy Download .nbib Format: NLM
Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide.

Turkish journal of pharmaceutical sciences

Shirinzadeh H, Süzen S, Altanlar N, Westwell AD.
PMID: 32454672
Turk J Pharm Sci. 2018 Dec;15(3):291-297. doi: 10.4274/tjps.55707. Epub 2018 Nov 20.

OBJECTIVES: In new antimicrobial drug development studies, indole and its derivatives create an important class of compounds. In addition, azoles and their derivatives were recognized to be associated with a variety of biologic activities such as antibacterial and antifungal....

Cite
Shirinzadeh H, Süzen S, Altanlar N, et al. Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide. Turk J Pharm Sci. 2018;15(3):291-297doi: 10.4274/tjps.55707.
Shirinzadeh, H., Süzen, S., Altanlar, N., & Westwell, A. D. (2018). Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide. Turkish journal of pharmaceutical sciences, 15(3), 291-297. https://doi.org/10.4274/tjps.55707
Shirinzadeh, Hanif, et al. "Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide." Turkish journal of pharmaceutical sciences vol. 15,3 (2018): 291-297. doi: https://doi.org/10.4274/tjps.55707
Shirinzadeh H, Süzen S, Altanlar N, Westwell AD. Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide. Turk J Pharm Sci. 2018 Dec;15(3):291-297. doi: 10.4274/tjps.55707. Epub 2018 Nov 20. PMID: 32454672; PMCID: PMC7227843.
Copy Download .nbib Format: NLM
Sleepiness and safety at work among night shift NHS nurses.

Occupational medicine (Oxford, England)

Westwell A, Cocco P, Van Tongeren M, Murphy E.
PMID: 34693974
Occup Med (Lond). 2021 Oct 25; doi: 10.1093/occmed/kqab137. Epub 2021 Oct 25.

BACKGROUND: Sleepiness associated with night shift working (NSW) is known to adversely affect workers' health and well-being. It has been associated with adverse safety outcomes and is a recognized workplace hazard among healthcare workers.AIMS: This study was aimed to...

Cite
Westwell A, Cocco P, Van Tongeren M, et al. Sleepiness and safety at work among night shift NHS nurses. Occup Med (Lond). 2021;doi: 10.1093/occmed/kqab137.
Westwell, A., Cocco, P., Van Tongeren, M., & Murphy, E. (2021). Sleepiness and safety at work among night shift NHS nurses. Occupational medicine (Oxford, England), . https://doi.org/10.1093/occmed/kqab137
Westwell, A, et al. "Sleepiness and safety at work among night shift NHS nurses." Occupational medicine (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/occmed/kqab137
Westwell A, Cocco P, Van Tongeren M, Murphy E. Sleepiness and safety at work among night shift NHS nurses. Occup Med (Lond). 2021 Oct 25; doi: 10.1093/occmed/kqab137. Epub 2021 Oct 25. PMID: 34693974; PMCID: PMC8574312.
Copy Download .nbib Format: NLM
The role and future potential of fluorinated biomarkers in positron emission tomography.

Expert opinion on drug discovery

Daniels S, Tohid SF, Velanguparackel W, Westwell AD.
PMID: 22823024
Expert Opin Drug Discov. 2010 Mar;5(3):291-304. doi: 10.1517/17460441003652967.

IMPORTANCE OF THE FIELD: Positron emission tomography (PET) is rapidly emerging as the functional imaging method of choice for in vivo imaging applications in a number of key areas of drug discovery and clinical pathology, but especially in oncology....

Cite
Daniels S, Tohid SF, Velanguparackel W, et al. The role and future potential of fluorinated biomarkers in positron emission tomography. Expert Opin Drug Discov. 2010;5(3):291-304doi: 10.1517/17460441003652967.
Daniels, S., Tohid, S. F., Velanguparackel, W., & Westwell, A. D. (2010). The role and future potential of fluorinated biomarkers in positron emission tomography. Expert opinion on drug discovery, 5(3), 291-304. https://doi.org/10.1517/17460441003652967
Daniels, Stephen, et al. "The role and future potential of fluorinated biomarkers in positron emission tomography." Expert opinion on drug discovery vol. 5,3 (2010): 291-304. doi: https://doi.org/10.1517/17460441003652967
Daniels S, Tohid SF, Velanguparackel W, Westwell AD. The role and future potential of fluorinated biomarkers in positron emission tomography. Expert Opin Drug Discov. 2010 Mar;5(3):291-304. doi: 10.1517/17460441003652967. PMID: 22823024.
Copy Download .nbib Format: NLM
Sleepiness and safety at work among night shift NHS nurses.

Occupational medicine (Oxford, England)

Westwell A, Cocco P, Van Tongeren M, Murphy E.
PMID: 34693974
Occup Med (Lond). 2021 Dec 24;71(9):439-445. doi: 10.1093/occmed/kqab137.

BACKGROUND: Sleepiness associated with night shift working (NSW) is known to adversely affect workers' health and well-being. It has been associated with adverse safety outcomes and is a recognized workplace hazard among healthcare workers.AIMS: This study was aimed to...

Cite
Westwell A, Cocco P, Van Tongeren M, et al. Sleepiness and safety at work among night shift NHS nurses. Occup Med (Lond). 2021;71(9):439-445doi: 10.1093/occmed/kqab137.
Westwell, A., Cocco, P., Van Tongeren, M., & Murphy, E. (2021). Sleepiness and safety at work among night shift NHS nurses. Occupational medicine (Oxford, England), 71(9), 439-445. https://doi.org/10.1093/occmed/kqab137
Westwell, A, et al. "Sleepiness and safety at work among night shift NHS nurses." Occupational medicine (Oxford, England) vol. 71,9 (2021): 439-445. doi: https://doi.org/10.1093/occmed/kqab137
Westwell A, Cocco P, Van Tongeren M, Murphy E. Sleepiness and safety at work among night shift NHS nurses. Occup Med (Lond). 2021 Dec 24;71(9):439-445. doi: 10.1093/occmed/kqab137. PMID: 34693974; PMCID: PMC8574312.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 31 entries